Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting [Yahoo! Finance]
Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting
Beyond Air, Inc. (NASDAQ: XAIR) had its price target lowered by analysts at Truist Financial Co. from $10.00 to $8.00. They now have a "buy" rating on the stock.
Beyond Air (XAIR) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]
Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants